Anesiva Inc

Anesiva — Algorx Pharmaceuticals — Merger or Acquisition (October 2005)

43 slides from Anesiva's merger presentation, Oct 21, 2005

  1. Slide 1: Creating a Late-Stage Company Focused on Pain Management and Inflammation

    Creating a Late-Stage Company Focused on Pain Management and Inflammation Analyst / Investor Luncheon October 21, 2005

  2. Slide 2: Forward Looking Statements

    FORWARD LOOKING STATEMENTS This presentation includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “pla

  3. Slide 3: Forward Looking Statements (2)

    FORWARD LOOKING STATEMENTS (2) Additional Information and Where to Find It Corgentech Inc. intends to file a registration statement on Form S-4, and Corgentech and AlgoRx Pharmaceuticals, Inc. intend to file a related joint proxy statement/prospectus, in connection with the merger transaction involv

  4. Slide 4: Luncheon Agenda

    LUNCHEON AGENDA Combining AlgoRx and Corgentech ALGRX 3268: positive clinical data plus commercial potential ALGRX 4975: positive clinical data plus commercial potential Execution

  5. Slide 5: Combined Company

    COMBINED COMPANY Pain Management and Inflammation Sizable Patient Populations Unmet or Underserved Medical Needs Differentiated Products with Clear Advantages over Current Therapies Substantial Body of Preclinical and Clinical Data Clear Regulatory Pathways Faster, Cheaper Trials

  6. Slide 6: Prevalence of Pain in Seven Major Countries

    PREVALANCE OF PAIN IN SEVEN MAJOR COUNTRIES PATIENT NUMBERS Prevalence of post-operative pain 75,068,000 Prevalence of back pain 208,996,000 Prevalence of HIV and AIDS pain 847,000 Prevalence of diabetic neuropathy pain 13,243,000 Prevalence of osteoarthritic pain 46,610,000 Above indications are al

  7. Slide 7: Product Pipeline

    PRODUCT PIPELINE PRECLINICAL PHASE 1 PHASE 2 PHASE 3 ALGRX 3268 Pre-procedural analgesia (003) Pre-procedural analgesia (004) ALGRX 4975 * Post-surgical pain Morton’s neuroma Tendonitis NF-kB Decoy * Atopic dermatitis (eczema) ALGRX 1207 * Cutaneous neuropathic pain * Does not reflect comprehensive

  8. Slide 8: Creating a Late-Stage Company

    CREATING LATE-STAGE COMPANY Four product development programs focused on significant clinical problems with attractive market potential Each drug has unique mechanism of action offering risk diversification Each drug has potential for approval in multiple indications Each drug can be commercialized

  9. Slide 9: Luncheon Agenda

    LUNCHEON AGENDA Combining AlgoRx and Corgentech ALGRX 3268: positive clinical data plus commercial potential ALGRX 4975: positive clinical data plus commercial potential Execution

  10. Slide 10: ALGRX 3268 - Topical Local Anesthesia

    ALGRX 3268- TOPICAL LOCAL ANESTHESIA Indication Reduction of pain associated with venipunctures and intravenous line placements Two Phase 3 trials required for approval Key desirable product attributes Sterile, pre-filled, needle-free disposable delivery system (Powderject®) Rapid onset of action Wi

  11. Slide 11: ALGRX 3268 Rapid Onset of Action

    ALGRX 3268 Rapid Onset of Action Critical to Adoption of Product EMLA Package Insert for EMLA ALGRX 3268 Data from Phase 1 trial in 272 adults VAS, mm -10 -20 -30 Time after administration, minutes VAS, mm -10 -20 -30 Time after administration, minutes ALGRX 3268 has an onset within one minute, wher

  12. Slide 12: ALGRX 3268 Development

    ALGRX 3268 DEVELOPMENT Protocol Age Group Phase Total Patients Primary Endpoint Status Antecubital Fossa Adults 1 272 Safety and Efficacy Primary Endpoint Achieved Back of Hand Adults 1 183 Safety and Efficacy Primary Endpoint Achieved Pharmacokinetics Adults 1 38 Evaluate Circulating Lidocaine Prim

  13. Slide 13: Phase 3s: Pediatric Trials, Identical Protocols

    PHASE 3’s: PEDIATRIC TRIALS IDENTICAL PROTOCOLS Design U.S. multicenter, randomized, double-blind, placebo-controlled Number of subjects 500-600 subjects in each study Population Pediatric subjects of either gender (ages 3-18) Objectives Confirm efficacy, safety and tolerability of ALGRX 3268 vs. pl

  14. Slide 14: First Phase 3 Results

    FIRST PHASE 3 RESULTS Primary endpoint achieved (p=0.007) Statistically significantly less pain on needle insertion in treated group compared to placebo group assessed using FACES rating scale 574 patients at six U.S. clinical trial sites ALGRX 3268 group = 289 patients (ages 3-18) Placebo = 285 pat

  15. Slide 15: Phase 1 Results - Adults, Antecubital Fossa

    PHASE 1 RESULTS – ADULTS, ANTECUBITAL FOSSA Population 272 adults received ALGRX 3268 or placebo before venipuncture at antecubital fossa Three separate treatment groups Results Clinically and statistically significantly less pain on needle insertion in treated groups compared to placebo groups asse

  16. Slide 16: Phase 1 Results - Adults, Back of Hand

    PHASE 1 RESULTS – ADULTS, BACK OF HAND Population 183 adults received ALGRX 3268 or placebo before venipuncture in the back of hand Two separate treatment groups Results Statistically significantly less pain on needle insertion in treated groups compared to placebo groups assessed using VAS rating s

  17. Slide 17: Phase 2 Results - Pediatrics, Back of Hand

    PHASE 2 RESULTS – PEDIATRICS, BACK OF HAND Population 195 pediatric patients received ALGRX 3268 or placebo before venipuncture in the back of hand Two treatment levels across three separate age groups Results Statistically significantly less pain on needle insertion in two age groups compared to pl

  18. Slide 18: Phase 2 Results - Pediatrics, Antecubital Fossa

    PHASE 2 RESULTS — PEDIATRICS, ANTECUBITAL FOSSA Population 145 pediatric patients received ALGRX 3268 or placebo before venipuncture at the antecubital fossa Three treatment levels across three separate age groups Results Statistically significantly less pain on needle insertion in treated groups co

  19. Slide 19: Phase 2 Results - Pediatrics, Back of Hand

    PHASE 2 RESULTS – PEDIATRICS, BACK OF HAND Population 306 pediatric patients received ALGRX 3268 or placebo before venipuncture in the back of hand One treatment level across three separate age groups Primary endpoint achieved Statistically significantly less pain on needle insertion in treated grou

  20. Slide 20: Projected Timeline for ALGRX 3268

    PROJECTED TIMELINE FOR ALGRX 3268 Clinical Data from second Phase 3 trial (004) expected within two months Regulatory Reviewed as a drug by the FDA Analgesics and Acute Care Division Registration File NDA in 2006 Product approval in 2007

  21. Slide 21: Commercial Opportunities for ALGRX 3268

    Commercial Opportunities for ALGRX 3268

  22. Slide 22: ALGRX 3268: Venipuncture Markets

    ALGRX 3268: VENIPUNCTURE MARKETS PROCEDURE NUMBERS Pediatric in-hospital procedures 18,000,000 Adult in-hospital emergency room visits 89,000,000 Hemodialysis patient visits 46,800,000 Additional Target Market Includes the 66,000 Physician’s Offices, Clinical Labs and Blood Donation Centers in the U

  23. Slide 23: Pediatric In-Hospital Market

    PEDIATRIC IN-HOSPITAL MARKET Target market Only 2.1MM out of 18MM venipuncture procedures in children’s hospitals and large academic institutions utilize a topical local anesthetic today Low utilization of topical local anesthetics (12% of pediatric procedures) due to: slow onset of action lack of p

  24. Slide 24: ALGRX 3268 - Drug Class Comparison

    ALGRX 3268- DRUG CLASS COMPARISON ALGRX 3268 EMLA Efficacy +++ +++ Ease of Use Minimal Messy and requires Preparation covering Onset of Action 1 minute 60 minutes to several hours Duration 10-15 minutes 1-2 hours after removal Adverse Minimal erythema 37% blanching, Reactions 30% erythema

  25. Slide 25: ALGRX 3268: Topical Local Anesthesia Market Dynamics

    ALGRX 3268: TOPICAL LOCAL ANESTHESIA MARKET DYNAMICS Strong focus of pain management including treatment protocols and guidelines Increase in dedicated pediatric hospitals and specialized pediatric departments in larger general hospitals Continuing pressure on cost reduction and patient through-put

  26. Slide 26: ALGRX 3268 - Potential Pediatric Market

    ALGRX 3268- POTENTIAL PEDIATRIC MARKET Superior Product Profile + Promotional Efforts = Market Penetration and Market Growth STRAWMAN UNIT POTENTIAL ANNUAL POTENTIAL SALES PRICE PROCEDURES $12 - $16* 2mm $24mm - $32mm $12 - $16* 3mm $36mm - $48mm $12 - $16* 4mm $48mm - $64mm $12 - $16* 5mm $60mm - $

  27. Slide 27: ALGRX 3268: Phased Marketing Approach

    ALGRX 3268: PHASED MARKETING APPROACH Physician Offices, Clinical Labs, Blood Donation Centers Hemodialysis Centers In-hospital Adult (ER) In-hospital Pediatric 18M

  28. Slide 28: Luncheon Agenda

    LUNCHEON AGENDA Combining AlgoRx and Corgentech ALGRX 3268: positive clinical data plus commercial potential ALGRX 4975: positive clinical data plus commercial potential Execution

  29. Slide 29: ALGRX 4975 - VR1 Anesthetic

    ALGRX 4975 – VR1 ANESTHETIC Capsaicin Overview Administered locally at the site of pain Single administration may provide analgesia for weeks to months Non-opioid based Only reduces long-term noxious pain associated with C-neurons Does not affect other nerve fibers important for motor skills Activat

  30. Slide 30: ALGRX 4975: Proof of Concept Established

    ALGRX 4975: PROOF OF CONCEPT ESTABLISHED STUDY MODEL FOR TARGET MARKETS Bunionectomy Post-Surgical Pain Joint Replacement Morton’s Neuroma Local Neuropathic Pain Complex Regional Pain Syndrome (CRPS) Tendonitis / Osteoarthritis Musculoskeletal Pain Delay progression to surgery

  31. Slide 31: ALGRX 4975 Development

    ALGRX 4975 DEVELOPMENT Protocol Phase Total Patients Primary Endpoint Status Postsurgical Pain Bunion Removal Surgery 2 40 Time to Rescue Medication 72-hour Endpoint Achieved Bunion Removal Surgery 2 182 Magnitude of Pain Relief 24 and 72- hour Endpoints Achieved Hernia Repair 2 48 Magnitude and Dur

  32. Slide 32: Morton's Neuroma

    MORTON’S NEUROMA Type of localized post-trauma neuropathic pain Painful foot condition that typically occurs as a result of: Running Wearing high narrow shoes Excessive standing Neuroma (thickened nerve tissue) Forms as a result of injury to one of the nerves that leads to the toes Leads to numbness

  33. Slide 33: Phase 2 Results: Morton's Neuroma

    PHASE 2 RESULTS: MORTON’S NEUROMA Objectives Confirm efficacy, safety and tolerability of ALGRX 4975 vs. placebo administered by single injection into neuroma Design and population U.S. randomized, double-blind, placebo-controlled 58 subjects of either gender at two U.S. clinical trial sites ALGRX 4

  34. Slide 34: Commercial Opportunities for ALGRX 4975

    Commercial Opportunities for ALGRX 4975

  35. Slide 35: ALGRX 4975: U.S. Post-Surgical and Neuropathic Pain Markets

    ALGRX 4975: U.S. POST-SURGICAL AND NEUROPATHIC PAIN MARKETS PROCEDURE NUMBERS POST-SURGICAL PAIN Bunionectomy 709,000 Cholecystectomy 1,230,000 Total knee replacement 412,000 Total hip replacement 346,000 Hernia repair 825,000 Hysterectomy 789,090 LOCAL NEUROPATHIC PAIN 1,269,000 TOTAL 5,580,090

  36. Slide 36: Post-Op Pain Drug Comparison

    POST-OP PAIN DRUG COMPARISON ALGRX 4975 Opioids Efficacy +++ +++ Dosing Single application Frequent Duration Weeks Hours Onset of Rapid Rapid action Safety Cannot inject near Respiratory depression, large nerves nausea, vomiting, ileus

  37. Slide 37: ALGRX 4975: Post-Operative Pain Market

    ALGRX 4975: POST-OPERATIVE PAIN MARKET US post-operative pain market: $1.7 billion Virtually all patients experience some level of pain post operatively Pain in hospital associated with increased length of stay, longer recovery times, poorer patient outcomes

  38. Slide 38: ALGRX 4975: Neuropathic Pain Market

    ALGRX 4975: NEUROPATHIC PAIN MARKET No drugs indicated for Morton’s neuroma or other post trauma neuropathic pain syndromes Off label usage of Neurontin, Lidoderms, antidepressants and opioids US neuropathic pain market: $1.9 billion Despite employing concomitant treatment with several drugs with di

  39. Slide 39: Post-Trauma Neuropathic Pain: Background

    POST-TRAUMA NEUROPATHIC PAIN: BACKGROUND Approximately 1.2 million Americans suffer from a localized form of neuropathic pain resulting from trauma or surgery Pain lasting months and often severe and debilitating Occurs following 10% of general and 30% of orthopedic surgeries Most commonly associate

  40. Slide 40: ALGRX 4975: Blockbuster Potential

    ALGRX 4975: BLOCKBUSTER POTENTIAL Large surgical volume Small target audience Specialized sales forces

  41. Slide 41: Luncheon Agenda

    LUNCHEON AGENDA Combining AlgoRx and Corgentech ALGRX 3268: positive clinical data plus commercial potential ALGRX 4975: positive clinical data plus commercial potential Execution

  42. Slide 42: Delivering on Our Promises

    DELIVERING ON OUR PROMISES Report Clinical Data from First Phase 3 Trial of ALGRX 3268 Report Clinical Data from Phase 2 Trial of ALGRX 4975 for Morton’s Neuroma Report Clinical Data from Second Phase 3 Trial of ALGRX 3268

  43. Slide 43: Thank you for joining us for today's presentation

    Thank you for joining us for today’s presentation. For additional information about the proposed merger of Corgentech and AlgoRx, please visit www.corgentech.com and the other sources described in our forward looking statement slide.

Algorx Pharmaceuticals — Merger or Acquisition (October 2005) on 6ix